Copyright
©The Author(s) 2020.
World J Hepatol. Dec 27, 2020; 12(12): 1148-1157
Published online Dec 27, 2020. doi: 10.4254/wjh.v12.i12.1148
Published online Dec 27, 2020. doi: 10.4254/wjh.v12.i12.1148
Pathway | Gene | Frequency of alteration |
NADPH metabolism | IDH1/2 | 4-36 |
Chromatic remodeling | BAP1 | 9%-25% |
ARID1A | 11-36 | |
PBRM1 | 11-17 | |
Cell cycle regulation and DNA damage response | CDKN2A | 7 |
CDK6 | 7 | |
TP53 | 3-38 | |
BRCA1/2 | 4 | |
PI3K signaling | PIK3CA | 4-6 |
PTEN | 1-11 | |
Ras/Raf/MEK/ERK | EGFR | 2.2 |
KRAS | 9-24 | |
NRAS | 3.6 | |
BRAF | 3-22 | |
FGF | FGFR2 | 4-38 |
Good prognostic subclass | Poor prognostic subclass | |
GSE26566 | Periductal infiltrating type, perineural invasion; KRAS mutation, EGFR and HER2 signatures | |
GSE32225 | Well differentiated tumor; inflammation-related signatures | Poor differentiated tumor; RTK-related pathways (AKT, MET, RAS/RAF/MAPK); overexpression of EGFR; KRAS mutation |
GSE32879 | EMT-related signatures; TGFβ1, NCAM1, CD133 | |
GSE89749 | Fluke-negative; FGFR fusion; BAP1, IDH mutation | Fluke-positive; BRCA1/2, TP53 mutation; ERBB2 gain |
GSE107943 | Small duct type (cholangiolar type); underlying hepatitis, cirrhosis; metabolism-related signatures; FGFR2 fusion | Large duct type (bile duct type); Elevated CEA, CA 19-9; underlying cholangitis; P53, inflammation-related signatures; KRAS mutation |
TCGA1 | Mitochondria/metabolic-related signatures; IDH, BAP1 mutation | Inflammation-related pathways |
- Citation: Ahn KS, Kang KJ. Molecular heterogeneity in intrahepatic cholangiocarcinoma. World J Hepatol 2020; 12(12): 1148-1157
- URL: https://www.wjgnet.com/1948-5182/full/v12/i12/1148.htm
- DOI: https://dx.doi.org/10.4254/wjh.v12.i12.1148